Breast Cancer Gene Expression Test

A breast cancer gene expression test examines tumour activity to help estimate recurrence risk and guide treatment discussions.

The test measures patterns of gene activity in cancer tissue removed during a biopsy or surgery. It does not diagnose a lump by itself. Instead, it can add information after breast cancer has been diagnosed, alongside tumour size, grade, hormone receptor findings and other pathology results.

A laboratory uses a preserved tissue sample from the tumour. Usually, no separate procedure is needed. The pathology team confirms that enough suitable tissue is available, sends it to a specialised laboratory, and returns a report to the oncology team. The report is then discussed with the rest of the pathology and staging information.

Because the analysis is performed on tissue already collected, the test itself does not add a new needle, anaesthetic or recovery period. Its result is one decision-making tool, not a promise about what will happen. Accuracy depends on the assay, the quality of the sample and whether the tumour fits the group for which the test was designed. Ask which assay is being used and how its result will change your options.

An elevated or otherwise concerning result does not mean that treatment has failed or that cancer has spread. It may indicate a greater chance of recurrence or a potential benefit from additional treatment, depending on the test. Your oncologist combines it with clinical and pathology findings before discussing chemotherapy, endocrine treatment, monitoring or another plan.

Gene expression testing looks at activity patterns rather than a single inherited gene. It is different from genetic testing that estimates inherited cancer risk for relatives. Results are interpreted in the context of the diagnosed [Breast Cancer](/conditions/breast-cancer/), not as a stand-alone answer.

It may be considered when the cancer has features that make the value of chemotherapy uncertain, such as certain hormone receptor and HER2 findings. It is not suitable for every breast tumour. The oncology team considers the tumour biology, lymph-node findings, menopausal status and the treatment question that needs answering.

The process commonly follows these steps: review the pathology; identify and release an adequate tissue sample; send it to the testing laboratory; receive and explain the report; and combine the result with examination, imaging and pathology findings. The final decision should reflect your values as well as the clinical information.

There is no recovery from the laboratory analysis itself. Recovery relates to the biopsy or operation that supplied the tissue. Results may take time to process; during that interval, keep planned appointments and ask when the report will be reviewed with you.

The main concern is interpretation: a result may not provide a clear answer, and it cannot account for every feature of an individual cancer. Testing can also create anxiety while you wait. Tell the team if you need the report explained in plain language or want a second pathology opinion.

Treatment planning may rely on pathology, tumour stage, imaging, physical examination and established clinical factors when gene expression testing is not appropriate. Some people may discuss a different assay or no genomic assay. The relevant comparison is how each option answers the specific treatment question.

Look for an oncology team that can explain why testing is being considered, which tissue will be used, when the report is expected and how each possible result could affect treatment. Bring your pathology report and a list of medicines and questions to the consultation. The laboratory approach may involve [Next-Generation Sequencing](/technology/next-generation-sequencing/).